32 completed, 5 terminated, 5 unknown, 1 withdrawn. 29 Phase 2, 9 Phase 1, 5 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Completed 24, Terminated 4, Unknown 1 |
| Phase 1 | 9 | Completed 7, Unknown 2 |
| Phase 3 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Not applicable | 2 | Unknown 2 |
Follow tositumomab I-131: new trials by email Literature Review of tositumomab I-131 trials Research Report on tositumomab I-131
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR. - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 96 | 2011-11-29 | 2023-08-16 |
| Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma Bexxar, Low Dose Methotrexate - Follicular Lymphoma | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 22 | 2011-07-01 | 2017-01-30 |
| S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma rituximab, tositumomab, cyclophosphamide - Lymphoma | Phase 2 | Completed | SWOG Cancer Research Network | 87 | 2009-04-01 | 2019-08-28 |
| Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Iodine I -01 Tositumomab (Bexxar), External Beam Radiation Therapy - Non-Hodgkin's Lymphoma, Follicular Lymphoma | Phase 2 | Terminated | University of Florida | 2 | 2007-09-01 | 2012-02-15 |
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma Bortezomib and Tositumomab I-131 - Follicular Lymphoma | Phase 2 | Terminated | Rush University Medical Center | 1 | 2007-05-01 | 2021-11-04 |
| Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy bortezomib, tositumomab - Non-Hodgkin's Lymphoma | Phase 1 | Completed | Weill Medical College of Cornell University | 31 | 2007-04-01 | 2018-08-13 |
| Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission Tositumomab and Iodine I 131 Tositumomab - Lymphoid Leukemia in Remission, Stage I Chronic Lymphocytic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 16 | 2007-02-01 | 2017-10-12 |
| Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant Bexxar - B-cell Lymphoma, Non-Hodgkin's Lymphoma | Phase 1 | Completed | University of Pennsylvania | 16 | 2007-02-01 | 2016-08-17 |
| Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy Bexxar (tositumomab), External beam radiotherapy (XRT), Potassium Iodide (KI) - Lymphoma, Non-Hodgkin | Phase 2 | Terminated | Stanford University | 8 | 2007-01-01 | 2017-03-29 |
| Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Autologous transplantation using rituxan/BEAM, Autologous transplantation using Bexxar/BEAM - Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 224 | 2005-12-01 | 2021-11-01 |
| S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma rituximab, cyclophosphamide, doxorubicin hydrochloride - Lymphoma | Phase 2 | Completed | SWOG Cancer Research Network | 86 | 2005-11-01 | 2016-03-07 |
| A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Ibritumomab Tiuxetan, Iodine I 131 Tositumomab - Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Large-Cell, Follicular | Phase 3 | Withdrawn | GlaxoSmithKline | 2005-09-01 | 2015-04-17 | |
| Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma Iodine I 131 Tositumomab - Multiple Myeloma | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 16 | 2005-08-01 | 2025-04-30 |
| Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma cyclophosphamide, etoposide, rituximab - Lymphoma, B-Cell | Phase 2 | Completed | Duke University | 39 | 2005-06-18 | 2017-05-30 |
| Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma fludarabine phosphate, peripheral blood stem cell transplantation, iodine I 131 tositumomab - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 38 | 2005-01-01 | 2014-08-06 |
| Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Tositumomab and Iodine I 131 Tositumomab, Rituximab - Lymphoma, Non-Hodgkin | Phase 3 | Completed | GlaxoSmithKline | 14 | 2004-10-01 | 2017-01-09 |
| Phase 2 Study of Bexxar in Relapsed/Refractory DLCL Bexxar, Acetaminophen, Diphenhydramine - Lymphoma | Phase 2 | Completed | Susan Knox | 9 | 2004-09-01 | 2017-03-30 |
| Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma Tositumomab 450 mg, Tositumomab 35 mg - Lymphoma, Non-Hodgkin | Phase 2 | Completed | GlaxoSmithKline | 93 | 2004-04-01 | 2012-08-13 |
| Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab Iodine I 131 Tositumomab - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 12 | 2003-04-01 | 2007-09-17 |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma Tositumomab and Iodine I 131 Tositumomab followed by CHOP - Lymphoma, Mantle-Cell | Phase 2 | Completed | GlaxoSmithKline | 25 | 2001-06-28 | 2019-12-04 |
Showing 20 of 43. Sign in to see all of them.
Lymphoma, Non-Hodgkin (29) · Lymphoma (12) · Lymphoma, Follicular (11) · Lymphoma, Mantle-Cell (6) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Large-Cell, Immunoblastic (5) · Lymphoma, B-Cell (4) · Burkitt Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Waldenstrom Macroglobulinemia (3) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large-Cell, Anaplastic (1) · Multiple Myeloma (1)
GlaxoSmithKline (16) · Corixa Corporation (6) · Fred Hutchinson Cancer Center (4) · SWOG Cancer Research Network (4) · University of Michigan Rogel Cancer Center (2) · University of Nebraska (2) · Duke University (1) · Memorial Sloan Kettering Cancer Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Rush University Medical Center (1) · Stanford University (1) · Susan Knox (1) · University of Florida (1) · University of Pennsylvania (1) · Weill Medical College of Cornell University (1)
United States (30) · United Kingdom (2) · Canada (1) · France (1)
Oliver W. Press, MD, PhD (3) · Ajay Gopal (2) · Jonathan W. Friedberg, MD (2) · Julie M. Vose, MD (2) · Susan J Knox (2) · Ajay K. Gopal, MD (1) · Andrew Zelenetz, MD,PhD (1) · David Rizzieri, MD (1) · Jia Ruan, MD, PhD (1) · Lisa Rimsza, MD (1) · Mark Kaminski, M.D. (1) · Mark Kaminski, MD (1) · Mary Horowitz, MD (1)
PMID 35787017, PMID 12738671, PMID 16110029, PMID 16896003, PMID 17312330, PMID 23233710, PMID 23478060, PMID 24528219, PMID 24530971, PMID 24898665, PMID 26832194, PMID 29356608, PMID 29396094, PMID 32800518, PMID 33558202, PMID 41714403, PMID 41746629
U10CA032102 (4), P01CA044991 (2), P30CA015704 (1), P30CA036727 (1), U01HL069294 (1)